<DOC>
	<DOCNO>NCT03023124</DOCNO>
	<brief_summary>Phase II randomize study comparison trabectedin versus doxorubicin plus dacarbazine patient advance solitary fibrous tumor</brief_summary>
	<brief_title>Study With Trabectedin Versus Adriamycin Plus Dacarbazine , Patients With Advanced Solitary Fibrous Tumor</brief_title>
	<detailed_description>Patients solitary fibrous tumor randomize receive 6 cycle trabectedin doxorubicin plus dacarbazine . In case progression unacceptable toxicity experimental treatment prior completion 6 cycle , patient offer cross arm ( trabectedin arm doxorubicin plus dacarbazine arm vice versa ) .</detailed_description>
	<mesh_term>Neoplasms , Fibrous Tissue</mesh_term>
	<mesh_term>Solitary Fibrous Tumors</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . The patient legal representative must able read understand inform consent form ( ICF ) must willing give write informed consent locally require authorisation studyspecific procedure , include screen evaluation , sample , analysis . 2 . Age ≥18 year 3 . Histological centrally molecularly confirm diagnosis solitary fibrous tumor ( inclusive last available tumor sample ) 4 . Locally advanced disease ( i.e . surgical resection local disease unfeasible radically , unaccepted patient , amenable become less demolitive , feasible , easy , cytoreduction ) and/or metastatic disease 5 . Measurable evaluable disease RECIST 6 . Evidence progression RECIST 6 month study entry 7 . Patients must cytotoxic chemotherapy naïve ( patient treat neoadjuvant/adjuvant chemotherapy include ) could receive previous target agent frontline setting . 8 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 9 . Adequate bone marrow function 10 . Adequate organ function 11 . Cardiac ejection fraction ≥50 % measure echocardiogram 12 . Female patient childbearing potential must negative pregnancy test within 7 day initiation cycle chemotherapy . Postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective method birth control throughout study . 13 . No history arterial and/or venous thromboembolic event within previous 12 month . 1 . Any prior treatment cytotoxic chemotherapy 2 . &gt; 1 line anticancer target agent 3 . Previous treatment investigational investigational agent within 14 day first day study drug dose 4 . Previous treatment radiation therapy within 14 day first day study drug dosing , patient recover adverse event due agent previously administer 5 . Previous radiotherapy 25 % bone marrow 6 . Major surgery within 4 week prior study entry 7 . Other primary malignancy &lt; 5 year clinically assess diseasefree interval , except basal cell skin cancer , cervical carcinoma situ , neoplasms judge entail low risk relapse 8 . Pregnancy breast feed 9 . Cardiovascular disease result New York Heart Association Functional Status &gt; 2 ( 24 ) . Medical history myocardial infarction &lt; 6 month prior initiation study treatment 10 . Medical history arterial thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism within 6 month prior initiation study treatment 11 . Known history human immunodeficiency virus infection 12 . Active chronic hepatitis B C require treatment antiviral therapy 13 . Medical history hemorrhage bleed event ≥ Grade 3 ( NCI‐CTCAE v 4.0 ) within 4 week prior initiation study treatment 14 . Evidence serious unstable illness , medical , psychological , social condition , could jeopardize safety subject and/or his/her compliance study procedure , may interfere subject 's participation study evaluation study result 15 . Known hypersensitivity study drug , study drug class , excipients formulation study drug 16 . Expected noncompliance medical regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>